One clinical trial just completed [274] and two ongoing (NCT01044654, and NCT01252641) [275,276] address the safety and efficacy of CCR5-ZFN-treated autologous cells, known as SB-728-T, in patients with chronic aviremic HIV infection under ART, including effects on CD4+ T-cell counts, viral load, and the ability of the cells to localize to anatomical reservoirs. The gene discussed is CCR5; the disease is HIV infectious disease.